S5:E219 David interviews Scott Pancoast, the Executive Chairman at Atticus Pharma, a spinout from Zylo Pharma where Scott is CEO. Atticus has 2 drug candidates from their Immunodermatology Platform and Scott updates listeners on the most recent developments at Atticus as they approach a liquidity event in the next few years. (recorded 2.18.26)
Follow David on X at https://x.com/DGRollingSouth
Connect On LinkedIn with David at https://www.linkedin.com/in/davidgrisell/
Follow Paul on X at https://x.com/PalmettoAngel
Connect On LinkedIn with Paul at
https://www.linkedin.com/in/paulclarkprivateequity/
We invite your feedback and suggestions at www.ventureinthesouth.com or email david@ventureinthesouth.com.
